A woman in her 40s from Western Australia, who recently received an AstraZeneca jab, has reportedly suffered a brain haemorrhage and is currently being treated for blood clots at the Royal Darwin Hospital (RDH), the Therapeutic Goods Administration said.

The woman is the second Australian to experience the potentially deadly blood clotting that health officials believe is linked to the AstraZeneca vaccine.

The woman was inoculated in WA and was initially admitted to Kununurra hospital in late March and diagnosed with a brain haemorrhage.

Attending physicians at the Kununurra hospital reportedly were not aware until early April that the patient had received the AstraZeneca vaccine two weeks earlier.

She was transferred to RDH for surgery and a few days later developed Deep-Vein Thrombosis in her limbs, The Australian reported.

It was not specified what treatment the woman is receiving. It was also unclear as to when exactly the patient was admitted to the RDH.

The ABC reported on Tuesday afternoon that the woman is in a stable condition and receiving treatment, while The Australian previously reported that she was in a serious condition in the Intensive Care Unit (ICU).

Health Minister Natasha Fyles said later this afternoon that the woman was in the ICU but “progressing well”.

The Therapeutic Goods Administration (TGA)’s Vaccine Safety Investigation Group have said the woman’s case, of thrombosis with low platelet counts, was possibly linked with the AstraZeneca vaccination.

“The VSIG meeting reviewed the case in detail, and assessed the case using an internationally accepted method to rate the level of certainty of a link between the event and vaccine,” the TGA said in a statement.

“The panel concluded that the case is similar to cases seen in Europe and the United Kingdom of a rare clotting disorder, referred to as ‘thrombosis with thrombocytopenia syndrome’ (TTS), because it included significant venous thrombosis (blood clots in the veins), thrombocytopenia (low blood platelet count) and blood test results consistent with other cases of TTS (notably, elevated D-dimer and antibodies to platelet factor 4).

“Diagnosis was complicated by some ambiguous imaging findings and the need to run additional confirmatory blood tests.”

The rate of rare blood clots associated with the vaccine now equates to one in 350,000 in Australians, the TGA said.

Last week, the NT Government announced it would “recalibrate” its vaccine rollout plan following advice that people under 50-years-old should not be inoculated with the UK-made AstraZeneca vaccine due to the risk of blood clots.

But the new vaccine plan details remain unclear as the Federal Government also refuses to put up revised timeframes.